Wedbush Has Pessimistic Outlook of Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 EPS estimates for Biogen in a note issued to investors on Thursday, February 13th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings per share of $3.82 for the quarter, down from their previous estimate of $3.97. The consensus estimate for Biogen's current full-year earnings is $15.84 per share. Wedbush also issued estimates for Biogen's FY2027 earnings at $17.85 EPS.

A number of other equities research analysts also recently issued reports on the stock. Citigroup reduced their price target on shares of Biogen from $160.00 to $145.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Truist Financial reduced their price target on shares of Biogen from $220.00 to $210.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Stifel Nicolaus downgraded shares of Biogen from a "buy" rating to a "hold" rating and set a $175.00 target price on the stock. in a research note on Monday, December 16th. Robert W. Baird boosted their price objective on Biogen from $294.00 to $300.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th. Finally, William Blair reiterated an "outperform" rating on shares of Biogen in a report on Monday, January 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $211.85.

Biogen Trading Up 0.3 %

Shares of Biogen stock traded up $0.40 during trading hours on Monday, hitting $137.08. The company's stock had a trading volume of 2,056,003 shares, compared to its average volume of 1,437,652. The stock has a market cap of $20.07 billion, a price-to-earnings ratio of 12.25, a P/E/G ratio of 1.47 and a beta of -0.08. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00. The firm has a fifty day moving average of $145.71 and a 200-day moving average of $171.46.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Institutional Trading of Biogen

Hedge funds have recently made changes to their positions in the stock. Pacer Advisors Inc. grew its position in shares of Biogen by 13,574.7% during the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company's stock worth $407,919,000 after acquiring an additional 2,648,024 shares during the last quarter. Norges Bank bought a new position in Biogen in the 4th quarter worth about $355,569,000. Van ECK Associates Corp grew its position in Biogen by 977.9% in the 4th quarter. Van ECK Associates Corp now owns 1,066,460 shares of the biotechnology company's stock worth $163,083,000 after purchasing an additional 967,523 shares during the last quarter. Invesco Ltd. increased its stake in shares of Biogen by 30.6% in the fourth quarter. Invesco Ltd. now owns 2,128,807 shares of the biotechnology company's stock valued at $325,537,000 after purchasing an additional 499,074 shares during the period. Finally, AQR Capital Management LLC raised its holdings in shares of Biogen by 982.0% during the fourth quarter. AQR Capital Management LLC now owns 539,692 shares of the biotechnology company's stock valued at $81,914,000 after buying an additional 489,811 shares during the last quarter. Institutional investors own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.